Molecular diagnostic and precision medicine firm Myriad Genetics has partnered with PATHOMIQ to add the latter’s artificial intelligence (AI) technology platform to its oncology portfolio.
PATHOMIQ develops AI-powered prognostic and predictive tests to enhance personalised medicine and support treatment decisions.
Under the partnership, Myriad Genetics will exclusively license PATHOMIQ’s PATHOMIQ_PRAD, an AI-powered prostate cancer platform, in the US.
The integration will allow the molecular diagnostic firm to provide urologists and radiation oncologists with molecular and AI-powered testing for better decision-making.
This includes decisions before treatment during biopsy for active surveillance and after surgery or radiation.
It complements Myriad Genetics’ current germline and tumour profiling offerings, aligning with National Comprehensive Cancer Network (NCCN) guidelines for prostate cancer care.
PATHOMIQ CEO and co-founder Rajat Roy said: “Our AI-powered model has been successfully validated across multiple medical institutions and pharmaceutical partners.
“Combining Myriad’s extensive clinical expertise and broad customer reach with PATHOMIQ’s AI technology platform will allow more personalised treatment options for clinicians and their patients.”
PATHOMIQ’s AI platform analyses complex cancer pathology to uncover hidden information from morphological structures across cancer pathology landscapes. It predicts patient outcomes, treatment responses, and genotype mutations.
This image-based technology delivers results in just one to two days after receiving digital images from patient samples.
The collaboration with PATHOMIQ expands Myriad Genetics’ prostate cancer testing portfolio, adding post-surgical treatment solutions.
It also aims to accelerate Simon level 1 evidence for Prolaris as well as PATHOMIQ_PRAD.
While PATHOMIQ_PRAD is currently for post-surgery prostate cancer patients, its foundational model holds potential for use in all solid tumour cancers diagnosed via biopsy with haematoxylin and eosin (H&E) staining.
PATHOMIQ’s AI platform is backed by key opinion leader engagement, six studies, and clinical trial data. The platform is protected by four issued patents and multiple pending patents, with specific use cases in prostate and breast cancer.
Myriad Genetics oncology president and chief clinical officer George Daneker said: “Along with our ProlarisProstate Cancer Prognostic Test, we are pleased to leverage PATHOMIQ’s prognostic and predictive capabilities across different phases of the patient journey in prostate cancer.
“Having both genetic and morphologic insights at the time of biopsy combined with the enhanced ability to predict disease recurrence after initial therapy can lead to more informed treatment decisions and enhance the potential for better patient outcomes.”
Myriad Genetics plans to commercially roll out its first AI-driven prostate cancer test later this year.
